TABLE 3.
Attribution of vaginal dryness symptoms to menopause among those who reported having vaginal dryness (n = 101)
| Characteristic | Attributed to menopause, n (%) |
P |
|---|---|---|
| Menopausal status | 0.023 | |
| Perimenopausal | 17 (22.7) | |
| Postmenopausal | 12 (46.2) | |
| HIV status | 0.079 | |
| Positive | 13 (22.0) | |
| Negative | 16 (38.1) | |
| Drug use in past 5 y | 0.40 | |
| Yes | 13 (25.0) | |
| No | 16 (32.7) | |
| Age, y | <0.001 | |
| <45 | 2 (5.3) | |
| ≥45 | 27 (42.9) | |
| Education, y | 0.008 | |
| <12 | 11 (18.6) | |
| ≥12 | 18 (42.9) | |
| Race | 0.51 | |
| Black | 17 (32.7) | |
| Hispanic | 10 (29.4) | |
| White | 1 (10.0) | |
| Mixed/other | 1 (20.0) | |
| Marital status | 0.96 | |
| Single/never married | 8 (29.6) | |
| Married/living together | 13 (29.5) | |
| Separated/divorced/widowed | 8 (26.7) | |
| Employed part time or more | 0.15 | |
| Yes | 8 (42.1) | |
| No | 21 (25.6) | |
| Receives public benefits | 0.40 | |
| Yes | 23 (27.1) | |
| No | 6 (37.5) | |
| Pregnancies (n = 179) | 0.96 | |
| 1–3 | 8 (32.0) | |
| 4–6 | 12 (26.7) | |
| 7–10 | 6 (30.0) | |
| ≥11 | 2 (33.3) | |
| CD4 cell count (n = 101) | 0.58 | |
| ≥501 | 7 (22.6) | |
| 201–500 | 3 (15.8) | |
| ≤200 | 3 (33.3) | |
| HAART use (n = 101) | 0.60 | |
| Yes | 6 (19.4) | |
| No | 7 (25.0) | |
| Smoking | 0.82 | |
| Never or former | 12 (30.0) | |
| Current | 17 (27.9) | |
| CAGE score | 0.59 | |
| 0–1 | 19 (30.6) | |
| ≥2 | 10 (25.6) | |
| Negative life events | 0.93 | |
| 0 | 1 (16.7) | |
| 1–2 | 6 (28.6) | |
| 3–5 | 15 (29.4) | |
| ≥6 | 7 (30.4) | |
| CES-D score | 0.43 | |
| <23 | 17 (32.1) | |
| ≥23 | 12 (25.0) | |
| Body mass index | 0.96 | |
| <25 | 9 (27.3) | |
| 25–29.99 | 7 (25.9) | |
| 30–34.99 | 7 (31.8) | |
| ≥35 | 6 (31.6) |
HIV, human immunodeficiency virus; HAART, highly active antiretroviral therapy; CES-D, Center for Epidemiologic Studies Depression Scale.